INM earnings: next report 2026-09-18, real EPS beat/miss history, analyst consensus Buy, P/E -0.00. Updated 2026-07-23.
InMed Pharmaceuticals (INM) Research Hub
InMed Pharmaceuticals (INM) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.29 USD (-1.53%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.00, market cap 0.00B. This hub links to the full technical, earnings and options research available for INM.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 1.29 USD (-1.53%) |
| 52-week range | 1.28 USD – 2.33 USD |
| Trend regime | Range |
| 14-day RSI | 35.5 (Bearish) |
| Trailing P/E | -0.00 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-18 |
Available research for INM
Covered Call on INM: how it works, illustrative setup around the real 1.29 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on INM: how it works, illustrative setup around the real 1.29 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on INM: how it works, illustrative setup around the real 1.29 USD price, max profit/loss, breakeven and when to use it. Educational.
INM technical analysis: range, last 1.29 USD, RSI 35.5, 52w range 1.28 USD–2.33 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is INM in?
InMed Pharmaceuticals (INM) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is INM in an uptrend or downtrend?
As of 2026-09-11, INM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is INM's trailing P/E ratio?
INM's trailing P/E is -0.00, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does INM next report earnings?
INM is next scheduled to report earnings on 2026-09-18, with a consensus EPS estimate of -94.44358 USD.